Why the study?
Does intravenous immunoglobulin improve long-term motor function outcomes in children with enterovirus 71-related acute flaccid paralysis?
Does intravenous immunoglobulin improve long-term motor function outcomes in children with enterovirus 71-related acute flaccid paralysis?
Answers are grounded in this paper and cite their sources.
In children with enterovirus 71-related acute flaccid paralysis, the use of intravenous immunoglobulin and initial disease severity may not reliably predict long-term motor function recovery.
The authors undertook long-term neurologic outcomes of 27 patients aged 0 to 15 years with enterovirus 71-related acute flaccid paralysis from June 1998 to July 2012. Motor function outcome was graded from class I (complete recovery) to class V (permanent paralytic limbs). Twelve of 20 patients (60%) who received intravenous immunoglobulin for treatment of acute flaccid paralysis had motor function outcomes in classes III to V. The median duration of follow-up was 6 months, during which time 7 of 13 patients (54%) with central nervous system infection, 3 of 6 patients (50%) with autonomic nervous system dysregulation, and 3 of 8 patients (37%) with heart failure showed motor function outcomes in classes III to V. These findings suggested that the usage of intravenous immunoglobulin and the severity of disease staging at disease onset might not be able to predict long-term motor function outcomes.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: